References
- Abe K and Saito H (2000) L-glutamate suppresses amyloid betaprotein-induced stellation of cultured rat cortical astrocytes. J Neurochem 74: 280-286 https://doi.org/10.1046/j.1471-4159.2000.0740280.x
- del Zoppo GJ and Mabuchi T (2003) Cerebral microvessel responses to focal ishchemia. J Cereb Blood Flow Metab 23:879-894 https://doi.org/10.1097/01.WCB.0000078322.96027.78
- Fernandez-Monreal M, Lopez-Atalava JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, Rossier J, Jarrige AC, Mackenzie ET, Colloc'h N, Ali C, and Cicien D (2004) Arginine 260 of the amino-terminal domain of NRI subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J Biol Chem 279: 50850-50856 https://doi.org/10.1074/jbc.M407069200
- Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, Donnan G, Heiss WD, Wahlgren NO; Spranger M, Boysen G, and Marler JR (1999) Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53: S3-S14 https://doi.org/10.1212/WNL.53.1.3
- Heidinger M, Kolb H, Krell HW, Jochum M, and Ries C (2006) Modulation of qutocrine TNF-alpha-stimulated matrix metallopreteinase-9 expression by mitogen activated protein kinases in THP-1 monocytic cells. J Biol Chem 387: 69-78 https://doi.org/10.1515/BC.2006.010
- Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, and Liu Y (2006) Tissue-type plasmonogen activator acts as a cytokine that triggers intracellular signal transduction and induced matrix metalliproteinase-9 gene expression. J Biol Chem 281: 2120-2127 https://doi.org/10.1074/jbc.M504988200
- Kim KC and Lee CH (2005) MAP kinase activation is required for the MMP-9 induction by TNF-stimulation. Arch Pharmacol Res 28: 1257-1262 https://doi.org/10.1007/BF02978209
- Lapchack PA, Arujo DM, Pakola S, Song D, Wei J, and Zivin JA (2002) Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 33: 2279-2284 https://doi.org/10.1161/01.STR.0000028267.09604.7B
- Lo EH, Dalkara T, and Moskowitz MA (2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4: 399-415 https://doi.org/10.1038/nrn1106
- Lo EH, Wang X, and Cuzner ML (2002) Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix proteinases. J Neurosci Res 69: 1-9 https://doi.org/10.1002/jnr.10270
- Marler JR, and Goldstein LB (2003) Stroke: t-PA and the clinic. Science 301: 1667 https://doi.org/10.1126/science.1090270
- Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, and Rogers JH (2002) Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 100: 103-117 https://doi.org/10.1016/S0169-328X(02)00132-8
- Rosenberg GA (2002) Matrix metalloproteinase in neuroinflammation. Glia 39: 279-291 https://doi.org/10.1002/glia.10108
- Shin M, Van C, and Boyd D (2002) An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 1589:311-316 https://doi.org/10.1016/S0167-4889(02)00195-7
- Sumii T, and Lo EH (2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33: 831-836 https://doi.org/10.1161/hs0302.104542
- Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Haung PL, Wang X, Montaner J, and Lo EH (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 36: 1954-1959 https://doi.org/10.1161/01.STR.0000177517.01203.eb
- Visse R, and Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-39 https://doi.org/10.1161/01.RES.0000070112.80711.3D
- Wang X, Lee SR, Ami K, Lee SR, Tsuji K, Rebeck GW, and Lo EH (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9: 1313-1317 https://doi.org/10.1038/nm926
- Wang X, Tsuji K, Lee SR, Ning MM, Furie KL, Buchan AM, and Lo EH (2004) Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemia stroke. Stroke 35(Suppl 1): 2726-2730 https://doi.org/10.1161/01.STR.0000143219.16695.af
- Wardlaw JM, Sandercock PA, and Berge E (2003) Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? Acumulative meta-analysis. Stroke 34: 1437-1442 https://doi.org/10.1161/01.STR.0000072513.72262.7E
- Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2: 502-511 https://doi.org/10.1038/35081571